PREVENTION OF BLOOD DISORDERS IN PATIENTS TREATED WITH A PPAR AGONIST

AR135465A1Pending Publication Date: 2026-09-23INVENTIVA

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: ARP20250100684
Authority / Receiving Office: AR · AR
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-11-08
Filing Date: 2025-03-14
Publication Date: 2026-09-23

Application Information

Patent Timeline

08 Nov 2024

Priority

14 Mar 2025

Application

ARP20250100684

23 Sep 2026

Publication

AR135465A1

IPC: A61K31/382; A61K31/428; A61K31/7034; A61K31/7042; A61K31/7048; A61K31/7056; A61K45/06; A61P3/00; A61P7/00; A61P7/06

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Need to check novelty before this filing date? Find Prior Art

No text content released.

Claims

The present invention relates to the use of sodium glucose transporter 2 (SGLT2) inhibitors for the prevention or delay of clinical complications of blood disorders, preferably anemia or clinical complications of anemia, in patients who have been treated, are being treated, or are planned to be treated with a PPAR agonist.

20. The use according to claim 19, characterized in that the deuterated form of lanifibranor is a compound of formula (1) wherein at least one of the groups R1 to R7 is a deuterium atom (D) and the other groups R1 to R7 are hydrogen atoms (H), preferably the deuterated form of lanifibranor is 4-(1-(2-deuterium-1,3-benzothiazol-6-yl)sulfonyl)-5-chloro-1H-indol-2-yl)butanoic acid or 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]-2,2,3,3,4,4-hexadeuteriumbutanoic acid.